See more : Northstar Gold Corp. (NSG.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Novartis AG (NVS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Novartis AG, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Kawasaki Kisen Kaisha, Ltd. (9107.T) Income Statement Analysis – Financial Results
- Mondi plc (MONDY) Income Statement Analysis – Financial Results
- Rand Mining Limited (RND.AX) Income Statement Analysis – Financial Results
- Volta Finance Limited (VTA.L) Income Statement Analysis – Financial Results
- Red Light Holland Corp. (TRUFF) Income Statement Analysis – Financial Results
Novartis AG (NVS)
About Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.66B | 51.83B | 52.88B | 49.90B | 48.68B | 53.17B | 50.14B | 49.44B | 50.39B | 53.63B | 58.83B | 57.56B | 59.38B | 51.56B | 45.10B | 42.58B | 38.95B | 36.75B | 32.53B | 28.25B | 24.86B | 23.15B | 19.34B | 21.83B | 20.42B | 23.04B |
| Cost of Revenue | 12.47B | 15.49B | 15.87B | 15.12B | 14.43B | 18.41B | 17.18B | 17.52B | 17.40B | 17.35B | 19.61B | 18.76B | 18.98B | 14.49B | 12.18B | 11.44B | 11.03B | 10.30B | 8.87B | 6.63B | 5.89B | 5.44B | 4.76B | 6.25B | 5.23B | 7.31B |
| Gross Profit | 34.19B | 36.34B | 37.01B | 34.78B | 34.25B | 34.76B | 32.96B | 31.92B | 32.98B | 36.29B | 39.22B | 38.81B | 40.39B | 37.07B | 32.92B | 31.15B | 27.92B | 26.45B | 23.66B | 21.62B | 18.97B | 17.71B | 14.58B | 15.59B | 15.19B | 15.73B |
| Gross Profit Ratio | 73.27% | 70.12% | 69.99% | 69.70% | 70.37% | 65.38% | 65.74% | 64.56% | 65.46% | 67.66% | 66.67% | 67.42% | 68.03% | 71.90% | 73.00% | 73.14% | 71.67% | 71.97% | 72.74% | 76.55% | 76.30% | 76.50% | 75.39% | 71.40% | 74.39% | 68.29% |
| Research & Development | 11.37B | 10.00B | 9.54B | 8.98B | 9.40B | 9.07B | 8.97B | 9.04B | 8.94B | 9.09B | 9.85B | 9.33B | 9.58B | 9.07B | 7.47B | 7.22B | 6.43B | 5.35B | 4.85B | 4.21B | 3.76B | 3.10B | 2.53B | 2.84B | 2.67B | 2.71B |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.47B | 2.14B | 2.19B | 2.48B | 2.62B | 3.06B | 2.94B | 2.97B | 2.48B | 2.28B | 2.25B | 2.13B | 1.96B | 1.74B | 1.54B | 0.00 | 8.98B | 7.66B | 7.94B | 6.95B | 1.29B |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.86B | 12.00B | 11.77B | 12.38B | 14.55B | 14.35B | 15.08B | 13.32B | 12.05B | 11.85B | 11.13B | 10.45B | 9.80B | 8.87B | 9.33B | 0.00 | 0.00 | 0.00 | 0.00 | 6.39B |
| SG&A | 12.49B | 14.25B | 14.89B | 14.20B | 14.37B | 16.47B | 15.00B | 14.19B | 14.25B | 14.99B | 17.61B | 17.29B | 18.05B | 15.80B | 14.33B | 14.10B | 13.26B | 12.41B | 11.54B | 10.41B | 9.33B | 8.98B | 7.66B | 7.94B | 6.95B | 7.68B |
| Other Expenses | 559.00M | 2.90B | 895.00M | 1.45B | 1.40B | 1.05B | 362.00M | 417.00M | 824.00M | 1.12B | 852.00M | 672.00M | 1.76B | 680.00M | 1.14B | 867.00M | 1.45B | 741.00M | 363.00M | 463.00M | 0.00 | 0.00 | 0.00 | 0.00 | 949.00M | 0.00 |
| Operating Expenses | 24.42B | 27.15B | 25.32B | 24.63B | 25.17B | 26.59B | 24.33B | 23.65B | 24.01B | 25.20B | 28.31B | 27.29B | 29.39B | 25.55B | 22.94B | 22.18B | 21.13B | 18.50B | 16.75B | 15.08B | 13.08B | 12.08B | 10.18B | 10.78B | 10.57B | 10.39B |
| Cost & Expenses | 36.89B | 42.63B | 41.19B | 39.75B | 39.59B | 45.00B | 41.51B | 41.17B | 41.41B | 42.55B | 47.92B | 46.05B | 48.38B | 40.04B | 35.12B | 33.62B | 32.17B | 28.80B | 25.62B | 21.71B | 18.98B | 17.52B | 14.94B | 17.03B | 15.80B | 17.69B |
| Interest Income | 627.00M | 379.00M | 71.00M | 91.00M | 245.00M | 294.00M | 110.00M | 43.00M | 33.00M | 33.00M | 34.00M | 50.00M | 62.00M | 103.00M | 156.00M | 306.00M | 423.00M | 367.00M | 405.00M | 388.00M | 323.00M | 416.00M | 293.00M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 855.00M | 837.00M | 811.00M | 869.00M | 850.00M | 957.00M | 777.00M | 707.00M | 655.00M | 704.00M | 683.00M | 724.00M | 751.00M | 692.00M | 551.00M | 290.00M | 237.00M | 266.00M | 294.00M | 261.00M | 243.00M | 259.00M | 218.00M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.28B | 6.71B | 5.43B | 5.11B | 5.83B | 5.21B | 5.21B | 5.35B | 5.58B | 4.75B | 4.99B | 4.95B | 5.79B | 3.42B | 2.30B | 2.67B | 2.86B | 1.99B | 1.72B | 1.34B | 1.28B | 690.00M | 585.00M | 918.00M | 949.00M | 1.01B |
| EBITDA | 18.29B | 14.73B | 17.13B | 15.24B | 15.01B | 14.14B | 13.90B | 13.19B | 14.36B | 17.66B | 15.90B | 16.92B | 17.09B | 15.81B | 12.77B | 12.46B | 10.58B | 10.18B | 8.78B | 7.97B | 7.26B | 5.90B | 4.41B | 5.63B | 5.56B | 6.35B |
| EBITDA Ratio | 39.19% | 31.62% | 62.52% | 34.49% | 32.08% | 40.91% | 31.71% | 30.42% | 28.51% | 33.05% | 27.89% | 29.40% | 29.20% | 30.67% | 28.18% | 28.96% | 26.75% | 28.62% | 28.21% | 29.63% | 29.21% | 25.50% | 22.82% | 24.68% | 25.46% | 27.58% |
| Operating Income | 9.77B | 9.20B | 26.95B | 10.15B | 9.09B | 8.17B | 8.63B | 8.27B | 8.98B | 11.09B | 10.91B | 11.51B | 11.00B | 11.53B | 9.98B | 8.96B | 6.78B | 7.95B | 6.91B | 6.54B | 5.89B | 5.63B | 4.39B | 4.81B | 4.62B | 5.35B |
| Operating Income Ratio | 20.94% | 17.75% | 50.96% | 20.35% | 18.67% | 15.37% | 17.21% | 16.72% | 17.82% | 20.68% | 18.54% | 20.00% | 18.52% | 22.35% | 22.13% | 21.05% | 17.41% | 21.63% | 21.23% | 23.15% | 23.68% | 24.34% | 22.72% | 22.01% | 22.62% | 23.20% |
| Total Other Income/Expenses | -646.00M | 425.00M | -16.15B | -274.00M | -146.00M | -746.00M | -811.00M | -451.00M | -843.00M | 1.18B | -176.00M | -271.00M | -225.00M | 176.00M | -60.00M | 94.00M | 294.00M | -219.00M | 360.00M | -129.00M | -155.00M | 64.00M | 367.00M | 789.00M | 714.00M | 408.43M |
| Income Before Tax | 9.12B | 8.37B | 26.14B | 9.88B | 8.94B | 13.84B | 9.00B | 7.82B | 8.13B | 12.27B | 10.74B | 11.24B | 10.77B | 11.70B | 9.92B | 9.50B | 7.49B | 8.30B | 7.27B | 6.91B | 6.07B | 6.29B | 5.11B | 5.51B | 5.34B | 5.79B |
| Income Before Tax Ratio | 19.55% | 16.15% | 49.43% | 19.80% | 18.37% | 26.02% | 17.95% | 15.81% | 16.14% | 22.88% | 18.25% | 19.53% | 18.14% | 22.70% | 22.00% | 22.31% | 19.22% | 22.59% | 22.34% | 24.46% | 24.40% | 27.17% | 26.42% | 25.22% | 26.16% | 25.14% |
| Income Tax Expense | 551.00M | 1.42B | 2.12B | 1.81B | 1.79B | 1.22B | 1.30B | 1.12B | 1.11B | 1.55B | 1.44B | 1.63B | 1.53B | 1.73B | 1.47B | 1.34B | 947.00M | 1.28B | 1.12B | 1.13B | 1.01B | 1.07B | 869.00M | 1.11B | 1.15B | 1.37B |
| Net Income | 14.85B | 6.96B | 24.02B | 8.07B | 7.15B | 12.61B | 7.70B | 6.71B | 17.78B | 10.21B | 9.18B | 9.51B | 9.11B | 9.79B | 8.40B | 8.20B | 11.95B | 7.18B | 6.13B | 5.77B | 5.02B | 5.22B | 4.24B | 4.40B | 4.19B | 4.41B |
| Net Income Ratio | 31.83% | 13.42% | 45.43% | 16.18% | 14.68% | 23.72% | 15.36% | 13.58% | 35.29% | 19.04% | 15.60% | 16.51% | 15.35% | 18.99% | 18.62% | 19.24% | 30.67% | 19.52% | 18.85% | 20.42% | 20.17% | 22.56% | 21.92% | 20.13% | 20.51% | 19.13% |
| EPS | 7.15 | 3.19 | 10.71 | 3.54 | 3.12 | 5.44 | 3.28 | 2.82 | 7.40 | 4.21 | 3.76 | 3.93 | 3.75 | 4.28 | 3.70 | 3.62 | 5.15 | 3.06 | 2.63 | 2.28 | 1.99 | 1.88 | 1.49 | 1.70 | 0.62 | 0.33 |
| EPS Diluted | 7.10 | 3.17 | 10.63 | 3.52 | 3.08 | 5.38 | 3.25 | 2.80 | 7.29 | 4.13 | 3.70 | 3.89 | 3.70 | 4.26 | 3.69 | 3.59 | 5.13 | 3.04 | 2.62 | 2.27 | 1.97 | 1.84 | 1.49 | 1.70 | 0.62 | 0.33 |
| Weighted Avg Shares Out | 2.08B | 2.18B | 2.24B | 2.28B | 2.29B | 2.32B | 2.35B | 2.38B | 2.40B | 2.43B | 2.44B | 2.42B | 2.38B | 2.29B | 2.27B | 2.27B | 2.32B | 2.35B | 2.33B | 2.36B | 2.38B | 2.52B | 2.57B | 2.63B | 2.62B | 2.74B |
| Weighted Avg Shares Out (Dil) | 2.09B | 2.20B | 2.26B | 2.30B | 2.32B | 2.34B | 2.37B | 2.40B | 2.44B | 2.47B | 2.48B | 2.44B | 2.41B | 2.30B | 2.28B | 2.28B | 2.33B | 2.36B | 2.34B | 2.37B | 2.41B | 2.57B | 2.58B | 2.63B | 2.62B | 2.74B |
Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Novartis (NVS) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates...
Novartis Posts Results Above Estimates, Raises Outlook
Novartis (NVS) on Tuesday posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali.
The Zacks Analyst Blog Novartis, Reddit and Check Point Software Technologies
Novartis, Reddit and Check Point Software Technologies are included in this Analyst Blog.
Novartis hikes FY forecast after Q3 profit beat
Novartis posts Q3 earnings with 10 per cent sales growth and 20 per cent core income growth. The drug maker has also hiked its FY guidance.
Novartis: we are exploring obesity drugs but other areas provide growth for years
Novartis said on Tuesday it was doing early research on next-generation obesity drugs that could be more tolerable or given at longer intervals but its current focus on other disease areas would provide for sales growth well into the 2030s.
Novartis lifts 2024 guidance for 3rd time on wider use of its drugs
Swiss drugmaker Novartis raised its 2024 earnings guidance for the third time on Tuesday, driven by wider use of its prescription drugs.
Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance
Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +10% (cc 1 , +9% USD) with core operating income up +20% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (+26% cc), Cosentyx (+28%...
This Biotech Stock Has Doubled Its Value Today—Here's Why
Shares of Monte Rosa Therapeutics (GLUE) more than doubled Monday after the biotechnology company struck an exclusive development and commercialization license agreement with Novartis (NVS) for its treatments for immune system diseases that could be worth more than $2 billion.
Buy 3 Stocks Likely to Gain on Potential Q3 Earnings Beat
We have narrowed our search to three large-cap stocks set to report earnings results tomorrow. These are: NVS, RDDT, CHKP.
Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash
Monte Rosa Therapeutics, Inc. secured a $150 million upfront partnership with Novartis to develop MRT-6160 for immune-mediated conditions, with potential $2.1 billion in milestone payments. Initial data from the phase 1 SAD/MAD study of MRT-6160 in healthy volunteers is expected...
Source: https://incomestatements.info
Category: Stock Reports